SCHEMBL12165576

SCHEMBL12165576

Cc1ccc2nc(N)c3nn(Cc4c(F)cccc4F)c(=O)n3c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 9/20 0.48
▸ ADORA2A P29274 8/20 0.48
▸ ADORA1 P30542 5/20 0.48
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ TLR7 Q9NYK1 1/20 0.36
▸ RORC P51449 1/20 0.36
▸ CDK1 P06493 2/20 0.36
▸ CDK2 P24941 2/20 0.36
▸ CDK4 P11802 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ IKBKB O14920 2/20 0.35
▸ CHUK O15111 2/20 0.35
▸ ERN1 O75460 1/20 0.35
▸ RPS6KA4 O75676 1/20 0.35
▸ PRKD3 O94806 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ CDK11B P21127 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12165526 0.92 ADORA3 (0.48) ADORA3ADORA2AADORA1MEN1KMT2A
SCHEMBL12165505 0.89 ADORA3 (0.50) ADORA3ADORA2AADORA1CDK1CDK2
SCHEMBL12165490 0.87 ADORA3 (0.44) ADORA3ADORA2AADORA1CDK1CDK2
SCHEMBL12165530 0.87 ADORA3 (0.46) ADORA3ADORA2AADORA1
SCHEMBL12165510 0.85 ADORA3 (0.56) ADORA3ADORA2AADORA1
SCHEMBL12188018 0.85 ADORA3 (0.42) ADORA3ADORA2AADORA1CDK1CDK2
SCHEMBL12165840 0.85 ADORA3 (0.43) ADORA3ADORA2AADORA1
SCHEMBL12165847 0.84 ADORA3 (0.55) ADORA3ADORA2AADORA1TP53MAPT
SCHEMBL12165766 0.84 ADORA2A (0.51) ADORA3ADORA2AADORA1
SCHEMBL12165551 0.83 ADORA2A (0.51) ADORA3ADORA2AADORA1KMT2ATLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8435994-B2 Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-05-07 — — US disclosed
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY MERCK SHARP & DOHME CORP. (US) 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY ADORA2A, ADORA3, ADORA1 ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback